Oncolytics Biotech Inc. (ONCY)
| Market Cap | 100.99M -13.3% |
| Revenue (ttm) | n/a |
| Net Income | -37.46M |
| EPS | -0.34 |
| Shares Out | 127.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 294,282 |
| Open | 0.7817 |
| Previous Close | 0.7688 |
| Day's Range | 0.7734 - 0.8020 |
| 52-Week Range | 0.7301 - 1.5100 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 4.24 (+435.35%) |
| Earnings Date | Aug 12, 2026 |
About ONCY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ONCY stock is "Buy." The 12-month stock price target is $4.24, which is an increase of 435.35% from the latest price.
News
Oncolytics reports pelareorep preclinical results
Oncolytics (ONCY) announced preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the initial treatment period, when pelareo...
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
Oncolytics price target lowered to $5 from $10 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Oncolytics (ONCY) to $5 from $10 and keeps a Buy rating on the shares. The firm updated the company’s…
Oncolytics aligns with FDA on path for REO 033 expansion study
Oncolytics (ONCY) announced that it has received written feedback from the FDA regarding the design of a potential pivotal Part B expansion of REO 033, the company’s ongoing randomized study…
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and...
Oncolytics Biotech Quarterly report: Q2 2026
Oncolytics Biotech has published its Q2 2026 quarterly earnings report on August 12, 2026.
Oncolytics announces FDA Fast Track designation for pelareorep
Oncolytics (ONCY) announced that the FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or...
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third F...
Oncolytics provides clinical, regulatory update on REO 033
Oncolytics (ONCY) provided a clinical and regulatory update on REO 033, the company’s randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan an...
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential ...
Oncolytics secures new patent for pelareorep manufacturing
Oncolytics (ONCY) Biotech announced that the United States Patent and Trademark Office has issued a new patent protecting its proprietary manufacturing process for pelareorep. The newly issued patent ...
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional pa...
Oncolytics Biotech Transcript: Jefferies Global Healthcare Conference 2026
Pelareorep, a systemically delivered oncolytic virus, is advancing in GI cancer trials with promising early data, especially in second-line metastatic colorectal cancer. Key near-term catalysts include interim results from a new controlled study and updates on patent protection.
Oncolytics promotes John McAdory to COO
Oncolytics (ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to COO. Additionally, McAdory has been promoted to COO. As COO,…
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically a...
Oncolytics announces initial data from pelareorep combination study
Oncolytics (ONCY) announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-...
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from ...
Oncolytics Biotech Slides: Investor presentation
Oncolytics Biotech has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Oncolytics Biotech to present data at ASCO 2026 on pelareorep
Oncolytics (ONCY) Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinical Oncology Annual Meeting at McCormick Place, Chicago...
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
Oncolytics Biotech Quarterly report: Q1 2026
Oncolytics Biotech has published its Q1 2026 quarterly earnings report on May 14, 2026.
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-M...
Oncolytics says in alignment with FDA following pelareorep Type C meeting
Oncolytics (ONCY) announced that a Type C meeting with the FDA has resulted in alignment on the design of a pivotal clinical study to support approval of pelareorep in patients…
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient ...
Oncolytics Biotech Slides: Investor presentation
Oncolytics Biotech has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.